Journal Article

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Rumi, Elisa, Vannucchi, Alessandro Maria, Komrokji, Rami, Gotlib, Jason, Cavalloni, Chiara, Giorgino, Toni, Benevolo, Giulia, Barbui, Tiziano, Mora, Barbara, Barraco, Daniela, Rotunno, Giada, Maffioli, Margherita, Caramella, Marianna, Kiladjian, Jean Jacques, Ruggeri, Marco, Pietra, Daniela, Palandri, Francesca, Passamonti, Francesco, Guglielmelli, Paola, Stefano, Valerio, Rambaldi, Alessandro, Cervantes, Francisco, Silver, Richard T., Albano, Francesco, Cazzola, Mario, Devos, Timothy

2019

Overview

Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient‐years. When including non‐melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient‐years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM. The incidence of second primary malignancies in postpolycythemia and post thrombocythemia myelofibrosis is around 1/100 patient‐years. There was no evidence of association between JAK inhibitor treatment and second primary malignancies development, with the exception of non‐melanoma skin cancer occurrence. In patients with polycythemia or thrombocythemia, the occurrence of myelofibrosis is not associated to that of second primary malignancies, leaving the two events pathogenetically independent.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Clinical Cancer Research / Cohort Studies / Female / Humans / Incidence / JAK inhibitors / Janus Kinase Inhibitors - therapeutic use / Male / Melanoma / Myelofibrosis / Neoplasms, Second Primary - drug therapy / Neoplasms, Second Primary - epidemiology / Original Research / Patients / Polycythemia Vera - drug therapy / Polycythemia Vera - epidemiology / Population studies / Primary Myelofibrosis - drug therapy / Primary Myelofibrosis - epidemiology / second malignancy / secondary myelofibrosis / Skin cancer / Skin Neoplasms - epidemiology / Thrombocythemia, Essential - epidemiology / Treatment Outcome